An Open-Label, Multiple-Dose, Dose- Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects with Solid Tumors or Lymphoma

Protocol No
VMONCOLOGY-VMO-01C
Principal Investigator
Sailaja Kamaraju
Phase
I
Summary
The major purposes of this study are to determine the maximum dose of the study drug that can be tolerated in humans, and once this dose is found, if it has any effect in patients with solid tumors or lymphoma.
Description
This is a Phase 1 study of orally administered VMD-928 in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: